{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:10:14Z","timestamp":1788765014891,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12015-026-11195-5","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:34:03Z","timestamp":1784943243000},"page":"3406-3416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measurable Residual Disease and the Unresolved Biology of Leukemic Stem Cells"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-3998","authenticated-orcid":false,"given":"Deepa","family":"Bhartiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitu","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"3","key":"11195_CR1","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1016\/S2352-3026(25)00002-X","volume":"12","author":"B Chin-Yee","year":"2025","unstructured":"Chin-Yee, B., Laplane, L., & Sujobert, P. (2025). Epistemic limitations of measurable residual disease in haematological malignancies. Lancet Haematol, 12(3), e224\u2013e229. https:\/\/doi.org\/10.1016\/S2352-3026(25)00002-X","journal-title":"Lancet Haematol"},{"key":"11195_CR2","doi-asserted-by":"publisher","first-page":"103348","DOI":"10.1016\/j.eclinm.2025.103348","volume":"86","author":"NS Chandhok","year":"2025","unstructured":"Chandhok, N. S., & Sekeres, M. A. (2025). Measurable residual disease in hematologic malignancies: a biomarker in search of a standard. EClinical Medicine, 86, 103348. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103348","journal-title":"EClinical Medicine"},{"issue":"6","key":"11195_CR3","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-024-02252-4","volume":"38","author":"J Chen","year":"2024","unstructured":"Chen, J., Gale, R. P., Hu, Y., Yan, W., Wang, T., & Zhang, W. (2024). Measurable residual disease (MRD)-testing in haematological and solid cancers. Leukemia, 38(6), 1202\u20131212. https:\/\/doi.org\/10.1038\/s41375-024-02252-4","journal-title":"Leukemia"},{"issue":"1","key":"11195_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/leu.2008.246","volume":"23","author":"N Misaghian","year":"2009","unstructured":"Misaghian, N., Ligresti, G., Steelman, L. S., Bertrand, F. E., B\u00e4secke, J., Libra, M., Nicoletti, F., Stivala, F., Milella, M., Tafuri, A., Cervello, M., Martelli, A. M., & McCubrey, J. A. (2009). Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia, 23(1), 25\u201342. https:\/\/doi.org\/10.1038\/leu.2008.246","journal-title":"Leukemia"},{"key":"11195_CR5","unstructured":"National Cancer Institute (2024). Cancer stat facts: Acute myeloid leukemia (AML). Available online at: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"11195_CR6","doi-asserted-by":"publisher","unstructured":"Radich, J., & Transplant (2024). MRD, and predicting relapse in AML. Blood. ;144(3):245\u2013247. https:\/\/doi.org\/10.1182\/blood.2024024870. PMID: 39023869.","DOI":"10.1182\/blood.2024024870"},{"key":"11195_CR7","doi-asserted-by":"publisher","first-page":"1724473","DOI":"10.3389\/fphar.2025.1724473","volume":"16","author":"MM Youssef","year":"2025","unstructured":"Youssef, M. M., & Park, C. Y. (2025). Flow cytometric detection of leukemic stem cells in Acute Myeloid Leukemia: current status and future directions. Frontiers In Pharmacology, 16, 1724473. https:\/\/doi.org\/10.3389\/fphar.2025.1724473","journal-title":"Frontiers In Pharmacology"},{"issue":"2","key":"11195_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10555-026-10322-5","volume":"45","author":"J Van Galen","year":"2026","unstructured":"Van Galen, J., Willis, S. D., Bains, A., & Small, S. H. (2026). Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development. Cancer And Metastasis Reviews, 45(2), 21. https:\/\/doi.org\/10.1007\/s10555-026-10322-5. Published 2026 Mar 27.","journal-title":"Cancer And Metastasis Reviews"},{"issue":"3","key":"11195_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/ejh.70000","volume":"115","author":"A Bruzzese","year":"2025","unstructured":"Bruzzese, A., Vigna, E., Martino, E. A., et al. (2025). Treatment-free remission in chronic myeloid leukemia: revisiting the W questions. European Journal Of Haematology, 115(3), 218\u2013231. https:\/\/doi.org\/10.1111\/ejh.70000","journal-title":"European Journal Of Haematology"},{"issue":"12","key":"11195_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake, T. L., & Vetrie, D. (2017). The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood, 129(12), 1595\u20131606. https:\/\/doi.org\/10.1182\/blood-2016-09-696013","journal-title":"Blood"},{"key":"11195_CR11","doi-asserted-by":"publisher","first-page":"1173701","DOI":"10.3389\/fonc.2023","volume":"13","author":"M Bou Zerdan","year":"2023","unstructured":"Bou Zerdan, M., Kassab, J., Saba, L., et al. (2023). Liquid biopsies and minimal residual disease in lymphoid malignancies. Frontiers In Oncology, 13, 1173701. https:\/\/doi.org\/10.3389\/fonc.2023","journal-title":"Frontiers In Oncology"},{"key":"11195_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02970-x","author":"Y Wang","year":"2026","unstructured":"Wang, Y., Li, C., Gale, R. P., et al. (2026). Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies. Leukemia. https:\/\/doi.org\/10.1038\/s41375-026-02970-x","journal-title":"Leukemia"},{"key":"11195_CR13","doi-asserted-by":"publisher","first-page":"1740112","DOI":"10.3389\/fonc.2025.1740112","volume":"15","author":"A Rago","year":"2026","unstructured":"Caravita di Toritto T and, & Rago, A. (2026). MRD in multiple myeloma: the clinical perspective. Frontiers In Oncology, 15, 1740112. https:\/\/doi.org\/10.3389\/fonc.2025.1740112","journal-title":"Frontiers In Oncology"},{"issue":"6","key":"11195_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41571-025-01017-x","volume":"22","author":"B Paiva","year":"2025","unstructured":"Paiva, B., Shi, Q., Puig, N., et al. (2025). Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nature Reviews. Clinical Oncology, 22(6), 424\u2013438. https:\/\/doi.org\/10.1038\/s41571-025-01017-x","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"11195_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-024-00479-6","volume":"13","author":"J Liu","year":"2024","unstructured":"Liu, J., Jiang, P., Lu, Z., et al. (2024). Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance. Exp Hematol Oncol, 13, 12. https:\/\/doi.org\/10.1186\/s40164-024-00479-6","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"11195_CR16","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1097\/HS9.0000000000000902","volume":"7","author":"P Robbe","year":"2023","unstructured":"Robbe, P., & Schuh, A. (2023). Genomic Stratification of Hematological Malignancies. Hemasphere, 7(6), e902. https:\/\/doi.org\/10.1097\/HS9.0000000000000902. Published 2023 May 25.","journal-title":"Hemasphere"},{"issue":"1","key":"11195_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/stem.160038","volume":"16","author":"TD Randall","year":"1998","unstructured":"Randall, T. D., & Weissman, I. L. (1998). Characterization of a population of cells in the bone marrow that phenotypically mimics hematopoietic stem cells: resting stem cells or mystery population? Stem Cells, 16(1), 38\u201348. https:\/\/doi.org\/10.1002\/stem.160038","journal-title":"Stem Cells"},{"issue":"5","key":"11195_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/sj.leu.2404171","volume":"20","author":"M Kucia","year":"2006","unstructured":"Kucia, M., Reca, R., Campbell, F. R., et al. (2006). A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4\u2009+\u2009stem cells identified in adult bone marrow. Leukemia, 20(5), 857\u2013869. https:\/\/doi.org\/10.1038\/sj.leu.2404171","journal-title":"Leukemia"},{"key":"11195_CR19","doi-asserted-by":"publisher","first-page":"1564964","DOI":"10.3389\/fbioe.2025.1564964","volume":"13","author":"K Thetchinamoorthy","year":"2025","unstructured":"Thetchinamoorthy, K., Jarczak, J., Kieszek, P., et al. (2025). Very small embryonic-like stem cells (VSELs) on the way for potential applications in regenerative medicine. Frontiers In Bioengineering And Biotechnology, 13, 1564964. https:\/\/doi.org\/10.3389\/fbioe.2025.1564964","journal-title":"Frontiers In Bioengineering And Biotechnology"},{"issue":"7459","key":"11195_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/499390a","volume":"499","author":"A Abbott","year":"2013","unstructured":"Abbott, A. (2013). Doubt cast over tiny stem cells. Nature, 499(7459), 390. https:\/\/doi.org\/10.1038\/499390a","journal-title":"Nature"},{"issue":"3","key":"11195_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/leu.2013","volume":"28","author":"MZ Ratajczak","year":"2014","unstructured":"Ratajczak, M. Z., Zuba-Surma, E., Wojakowski, W., et al. (2014). Very small embryonic-like stem cells (VSELs) represent a real challenge in stem cell biology: recent pros and cons in the midst of a lively debate. Leukemia, 28(3), 473\u2013484. https:\/\/doi.org\/10.1038\/leu.2013","journal-title":"Leukemia"},{"issue":"1","key":"11195_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humupd\/dmw030","volume":"23","author":"D Bhartiya","year":"2016","unstructured":"Bhartiya, D., Shaikh, A., Anand, S., et al. (2016). Endogenous, very small embryonic-like stem cells: critical review, therapeutic potential and a look ahead. Human Reproduction Update, 23(1), 41\u201376. https:\/\/doi.org\/10.1093\/humupd\/dmw030","journal-title":"Human Reproduction Update"},{"issue":"22","key":"11195_CR23","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1089\/scd.2018.0118","volume":"27","author":"D Bhartiya","year":"2018","unstructured":"Bhartiya, D., Patel, H., Ganguly, R., et al. (2018). Novel insights into adult and cancer stem cell biology. Stem Cells And Development, 27(22), 1527\u20131539. https:\/\/doi.org\/10.1089\/scd.2018.0118","journal-title":"Stem Cells And Development"},{"issue":"1","key":"11195_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12015-017-9781-x","volume":"14","author":"R Ganguly","year":"2018","unstructured":"Ganguly, R., Metkari, S., & Bhartiya, D. (2018). Dynamics of bone marrow VSELs and HSCs in response to treatment with gonadotropin and steroid hormones, during pregnancy and evidence to support their asymmetric\/symmetric cell divisions. Stem Cell Rev Rep, 14(1), 110\u2013124. https:\/\/doi.org\/10.1007\/s12015-017-9781-x","journal-title":"Stem Cell Rev Rep"},{"key":"11195_CR25","doi-asserted-by":"publisher","unstructured":"Shin, D. M., Zuba-Surma, E. K., Wu, W. (2009). Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells. Leukemia. ;23(11):2042\u20132051. https:\/\/doi.org\/10.1038\/leu. 2009.153.","DOI":"10.1038\/leu"},{"issue":"2","key":"11195_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.exphem.2010.10.007","volume":"39","author":"J Ratajczak","year":"2011","unstructured":"Ratajczak, J., Wysoczynski, M., Zuba-Surma, E., et al. (2011). Adult murine bone marrow-derived very small embryonic-like stem cells differentiate into the hematopoietic lineage after coculture over OP9 stromal cells. Experimental Hematology, 39(2), 225\u2013237. 10.1016\/j. exphem.2010.10.007","journal-title":"Experimental Hematology"},{"issue":"2","key":"11195_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12015-016-9714-0","volume":"13","author":"A Shaikh","year":"2017","unstructured":"Shaikh, A., Anand, S., Kapoor, S., Ganguly, R., & Bhartiya, D. (2017). Mouse bone marrow VSELs exhibit differentiation into three embryonic germ lineages and germ & hematopoietic cells in culture. Stem Cell Rev Rep, 13(2), 202\u2013216. https:\/\/doi.org\/10.1007\/s12015-016-9714-0","journal-title":"Stem Cell Rev Rep"},{"issue":"8","key":"11195_CR28","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/leu.2017.148","volume":"31","author":"MZ Ratajczak","year":"2017","unstructured":"RatajczakMZ (2017). Why are hematopoietic stem cells so \u2018sexy\u2019? on a search for developmental explanation. Leukemia, 31(8), 1671\u20131677. https:\/\/doi.org\/10.1038\/leu.2017.148","journal-title":"Leukemia"},{"issue":"8","key":"11195_CR29","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1007\/s12015-022-10424-x","volume":"18","author":"D Bhartiya","year":"2022","unstructured":"Bhartiya, D., Kaushik, A., Singh, P., & Sharma, D. (2022). Cancer initiates due to excessive self-renewal and blocked differentiation of tissue-resident, OCT-4 positive VSELs. Stem Cell Rev Rep, 18(8), 3112\u20133114. https:\/\/doi.org\/10.1007\/s12015-022-10424-x","journal-title":"Stem Cell Rev Rep"},{"issue":"19","key":"11195_CR30","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.3390\/ijms21196996","volume":"21","author":"P Scharf","year":"2020","unstructured":"Scharf, P., Broering, M. F., Oliveira da Rocha, G. H., & Farsky, S. H. P. (2020). Cellular and molecular mechanisms of environmental pollutants on hematopoiesis. International Journal Of Molecular Sciences, 21(19), 6996. https:\/\/doi.org\/10.3390\/ijms21196996","journal-title":"International Journal Of Molecular Sciences"},{"key":"11195_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tox.2016","volume":"374","author":"NS Fracchiolla","year":"2016","unstructured":"Fracchiolla, N. S., Annaloro, C., Guidotti, F., Fattizzo, B., & Cortelezzi, A. (2016). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) role in hematopoiesis and in hematologic diseases: A critical review. Toxicology, 374, 60\u201368. https:\/\/doi.org\/10.1016\/j.tox.2016","journal-title":"Toxicology"},{"key":"11195_CR32","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41598-021-81604-x","volume":"11","author":"A Foucault","year":"2021","unstructured":"Foucault, A., Vallet, N., Ravalet, N., et al. (2021). Occupational pesticide exposure increases risk of acute myeloid leukemia: a meta-analysis of case\u2013control studies including 3,955 cases and 9,948 controls. Scientific Reports, 11, 2007. https:\/\/doi.org\/10.1038\/s41598-021-81604-x","journal-title":"Scientific Reports"},{"issue":"4","key":"11195_CR33","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s12015-024-10694-7","volume":"20","author":"D Bhartiya","year":"2024","unstructured":"Bhartiya, D., Raouf, S., Pansare, K., Tripathi, A., & Tripathi, A. (2024). Initiation of cancer: the journey from mutations in somatic cells to epigenetic changes in tissue-resident VSELs. Stem Cell Rev Rep, 20(4), 857\u2013880. https:\/\/doi.org\/10.1007\/s12015-024-10694-7","journal-title":"Stem Cell Rev Rep"},{"key":"11195_CR34","doi-asserted-by":"publisher","first-page":"1446687","DOI":"10.3389\/fimmu.2024.1446687","volume":"15","author":"A Kr\u0119towska-Grunwald","year":"2024","unstructured":"Kr\u0119towska-Grunwald, A., Sawicka-\u017bukowska, M., Starosz, A., Krawczuk-Rybak, M., Moniuszko, M., & Grubczak, K. (2024). Selected stem cell populations in pediatric acute lymphoblastic leukemia. Frontiers In Immunology, 15, 1446687. https:\/\/doi.org\/10.3389\/fimmu.2024.1446687","journal-title":"Frontiers In Immunology"},{"issue":"23","key":"11195_CR35","doi-asserted-by":"publisher","first-page":"16671","DOI":"10.3390\/ijms242316671","volume":"24","author":"R Lahlil","year":"2023","unstructured":"Lahlil, R., Aries, A., Scrofani, M., Zanetti, C., Hennequin, D., & Dr\u00e9nou, B. (2023). Stem cell responsiveness to imatinib in chronic myeloid leukemia. International Journal Of Molecular Sciences, 24(23), 16671. https:\/\/doi.org\/10.3390\/ijms242316671","journal-title":"International Journal Of Molecular Sciences"},{"issue":"4","key":"11195_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/stmcls\/sxad015","volume":"41","author":"D Bhartiya","year":"2023","unstructured":"Bhartiya, D., Sharma, N., Dutta, S., Kumar, P., Tripathi, A., & Tripathi, A. (2023). Very small embryonic-like stem cells transform into cancer stem cells and are novel candidates for detecting\/monitoring cancer by a simple blood test. Stem Cells, 41(4), 310\u2013318. https:\/\/doi.org\/10.1093\/stmcls\/sxad015","journal-title":"Stem Cells"},{"issue":"10425","key":"11195_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(23)02830-1","volume":"403","author":"C Turnbull","year":"2024","unstructured":"Turnbull, C., Wald, N., Sullivan, R., et al. (2024). GRAIL-Galleri: why the special treatment? Lancet, 403(10425), 431\u2013432. https:\/\/doi.org\/10.1016\/S0140-6736(23)02830-1","journal-title":"Lancet"},{"issue":"5","key":"11195_CR38","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s12015-021-10167-1","volume":"17","author":"V Tripathi","year":"2021","unstructured":"Tripathi, V., Bhartiya, D., Vaid, A., et al. (2021). Quest for pan-cancer diagnosis\/prognosis ends with HrC test measuring Oct4A in peripheral blood. Stem Cell Rev Rep, 17(5), 1827\u20131839. https:\/\/doi.org\/10.1007\/s12015-021-10167-1","journal-title":"Stem Cell Rev Rep"},{"issue":"5","key":"11195_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/bies.201100025","volume":"33","author":"AM Soto","year":"2011","unstructured":"Soto, A. M., & Sonnenschein, C. (2011). The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays, 33(5), 332\u2013340. https:\/\/doi.org\/10.1002\/bies.201100025","journal-title":"Bioessays"},{"issue":"31","key":"11195_CR40","doi-asserted-by":"publisher","first-page":"e2505377122","DOI":"10.1073\/pnas.2505377122","volume":"122","author":"SA Frank","year":"2025","unstructured":"Frank, S. A. (2025). How cancer arises: Genetics releases, plasticity creates, genetics stabilizes. Proc Natl Acad Sci U S A, 122(31), e2505377122. https:\/\/doi.org\/10.1073\/pnas.2505377122","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"11195_CR41","doi-asserted-by":"publisher","first-page":"e3003052","DOI":"10.1371\/journal.pbio.3003052","volume":"23","author":"S Huang","year":"2025","unstructured":"Huang, S., Soto, A. M., & Sonnenschein, C. (2025). The end of the genetic paradigm of cancer. Plos Biology, 23(3), e3003052. https:\/\/doi.org\/10.1371\/journal.pbio.3003052","journal-title":"Plos Biology"},{"issue":"2\u20133","key":"11195_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10863-025-10059-w","volume":"57","author":"TN Seyfried","year":"2025","unstructured":"Seyfried, T. N., Lee, D. C., Duraj, T., et al. (2025). The Warburg hypothesis and the emergence of the mitochondrial metabolic theory of cancer. Journal Of Bioenergetics And Biomembranes, 57(2\u20133), 57\u201383. https:\/\/doi.org\/10.1007\/s10863-025-10059-w","journal-title":"Journal Of Bioenergetics And Biomembranes"},{"issue":"8","key":"11195_CR43","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1007\/s12015-025-10954-0","volume":"21","author":"D Bhartiya","year":"2025","unstructured":"Bhartiya, D. (2025). Will detecting somatic mutations three years prior to diagnosis help early prediction of cancer? Stem Cell Rev Rep, 21(8), 2807\u20132809. https:\/\/doi.org\/10.1007\/s12015-025-10954-0","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"11195_CR44","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s12015-026-11099-4","volume":"22","author":"D Bhartiya","year":"2026","unstructured":"Bhartiya, D. (2026). Epigenetic dysregulation of tissue-resident VSELs drives clonal events, including somatic mutations & eventually cancer. Stem Cell Rev Rep, 22(4), 2019\u20132022. https:\/\/doi.org\/10.1007\/s12015-026-11099-4","journal-title":"Stem Cell Rev Rep"},{"issue":"12","key":"11195_CR45","doi-asserted-by":"publisher","first-page":"9711","DOI":"10.1007\/s13277-015-3731-5","volume":"36","author":"JY Yin","year":"2015","unstructured":"Yin, J. Y., Tang, Q., Zhai, L. L., et al. (2015). High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia. Tumour Biology, 36(12), 9711\u20139716. https:\/\/doi.org\/10.1007\/s13277-015-3731-5","journal-title":"Tumour Biology"},{"issue":"22","key":"11195_CR46","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1089\/scd.2017.0134","volume":"26","author":"T Picot","year":"2017","unstructured":"Picot, T., Kesr, S., Wu, Y., et al. (2017). Potential Role of OCT4 in Leukemogenesis. Stem Cells And Development, 26(22), 1637\u20131647. https:\/\/doi.org\/10.1089\/scd.2017.0134","journal-title":"Stem Cells And Development"},{"issue":"7","key":"11195_CR47","doi-asserted-by":"publisher","first-page":"101042831771662","DOI":"10.1177\/1010428317716629","volume":"39","author":"T Picot","year":"2017","unstructured":"Picot, T., Aanei, C. M., Fayard, A., et al. (2017). Expression of embryonic stem cell markers in acute myeloid leukemia. Tumour Biology, 39(7), 1010428317716629. https:\/\/doi.org\/10.1177\/1010428317716629","journal-title":"Tumour Biology"},{"issue":"10","key":"11195_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/10245332.2018.1482050","volume":"23","author":"Y Xiang","year":"2018","unstructured":"Xiang, Y., & Zhou, X. (2018). Octamer-binding transcription factor 4 correlates with complex karyotype, FLT3-ITD mutation and poorer risk stratification, and predicts unfavourable prognosis in patients with acute myeloid leukaemia. Hematology, 23(10), 721\u2013728. https:\/\/doi.org\/10.1080\/10245332.2018.1482050","journal-title":"Hematology"},{"issue":"1","key":"11195_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s43046-024-00209-3","volume":"36","author":"S Aref","year":"2024","unstructured":"Aref, S., Khaled, O., Menshawy, N. E., et al. (2024). Significance of OCT3\/4 and SOX2 antigens expression by leukemic blast cells in adult acute leukemia. J Egypt Natl Canc Inst, 36(1), 5. https:\/\/doi.org\/10.1186\/s43046-024-00209-3","journal-title":"J Egypt Natl Canc Inst"},{"issue":"1","key":"11195_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41389-025-00553-6","volume":"14","author":"Q Zhou","year":"2025","unstructured":"Zhou, Q., Li, Z., Zhao, P., Guan, Y., Chu, H., & Xi, Y. (2025). FLT3 inhibition upregulates OCT4\/NANOG to promote maintenance and TKI resistance of FLT3-ITD+ acute myeloid leukemia. Oncogenesis, 14(1), 7. https:\/\/doi.org\/10.1038\/s41389-025-00553-6","journal-title":"Oncogenesis"},{"issue":"4","key":"11195_CR51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3892\/br.2025.2042","volume":"23","author":"J Organista-Nava","year":"2025","unstructured":"Organista-Nava, J., G\u00f3mez-G\u00f3mez, Y., G\u00f3mez-S\u00e1nchez, C. Y., et al. (2025). Expression of Oct3\/4 isoforms and its association with the risk of relapse in acute lymphoblastic leukemia. Biomed Rep, 23(4), 164. https:\/\/doi.org\/10.3892\/br.2025.2042","journal-title":"Biomed Rep"},{"issue":"2","key":"11195_CR52","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/jcm14020392","volume":"14","author":"S Rocco","year":"2025","unstructured":"Rocco, S., Maglione, A., Schiavo, V., Ferrando, A., Fava, C., Cilloni, D., Pergolizzi, B., & Panuzzo, C. (2025). Tyrosine kinase inhibitor therapy enhances stem cells profile and may contribute to survival ofchronic myeloid leukemia stem cells. J Clin Med, 14(2), 392. https:\/\/doi.org\/10.3390\/jcm14020392","journal-title":"J Clin Med"},{"issue":"1","key":"11195_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1172\/JCI43605","volume":"121","author":"A Perl","year":"2011","unstructured":"Perl, A., & Carroll, M. (2011). BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest, 121(1), 22\u201325. https:\/\/doi.org\/10.1172\/JCI43605","journal-title":"J Clin Invest"},{"issue":"1","key":"11195_CR54","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011). Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest, 121(1), 396\u2013409. https:\/\/doi.org\/10.1172\/JCI35721","journal-title":"J Clin Invest"},{"issue":"5","key":"11195_CR55","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/ijlh.13528","volume":"43","author":"O Ilhan","year":"2021","unstructured":"Ilhan, O., Narli Ozdemir, Z., Dalva, K., et al. (2021). Leukemic stem cells shall be searched in the bone marrow before tyrosine kinase inhibitor-discontinuation in chronic myeloid leukemia. Int J Lab Hematol, 43(5), 1110\u20131116. https:\/\/doi.org\/10.1111\/ijlh.13528","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"11195_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.beha.2019.02.001","volume":"32","author":"J Tang","year":"2019","unstructured":"Tang, J., Zhu, N., Rao, S., & Carlson, K. S. (2019). Stem cell damage after chemotherapy- can we do better? Best Practice & Research. Clinical Haematology, 32(1), 31\u201339. 10.1016\/j. beha.2019.02.001","journal-title":"Best Practice & Research. Clinical Haematology"},{"issue":"1","key":"11195_CR57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13287-024-03853-7","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y., Chen, X., Wang, X., et al. (2024). Insights into ionizing radiation-induced bone marrow hematopoietic stem cell injury. Stem Cell Research & Therapy, 15(1), 222. https:\/\/doi.org\/10.1186\/s13287-024-03853-7. Published 2024 Jul 23.","journal-title":"Stem Cell Research & Therapy"},{"issue":"1","key":"11195_CR58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13287-016-0311-6","volume":"7","author":"A Shaikh","year":"2016","unstructured":"Shaikh, A., Bhartiya, D., Kapoor, S., & Nimkar, H. (2016). Delineating the effects of 5-fluorouracil and follicle-stimulating hormone on mouse bone marrow stem\/progenitor cells. Stem Cell Research & Therapy, 7(1), 59. https:\/\/doi.org\/10.1186\/s13287-016-0311-6. Published 2016 Apr 19.","journal-title":"Stem Cell Research & Therapy"},{"key":"11195_CR59","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12958-015-0121-1","volume":"13","author":"P Kurkure","year":"2015","unstructured":"Kurkure, P., Prasad, M., Dhamankar, V., & Bakshi, G. (2015). Very small embryonic-like stem cells (VSELs) detected in azoospermic testicular biopsies of adult survivors of childhood cancer. Reproductive Biology And Endocrinology : Rb&E, 13, 122. https:\/\/doi.org\/10.1186\/s12958-015-0121-1","journal-title":"Reproductive Biology And Endocrinology : Rb&E"},{"issue":"2","key":"11195_CR60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/diseases14020050","volume":"14","author":"E Apostolidou","year":"2026","unstructured":"Apostolidou, E., Georgoulis, V., Leonardos, D., Benetatos, L., Kapsali, E., & Hatzimichael, E. (2026). Decoding leukemic stem cells in AML: From identification to targeted eradication. Diseases, 14(2), 50. https:\/\/doi.org\/10.3390\/diseases14020050","journal-title":"Diseases"},{"issue":"6464","key":"11195_CR61","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T., Sirard, C., Vormoor, J., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367(6464), 645\u2013648. https:\/\/doi.org\/10.1038\/367645a0","journal-title":"Nature"},{"issue":"15","key":"11195_CR62","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","volume":"119","author":"JM Gerber","year":"2012","unstructured":"Gerber, J. M., Smith, B. D., Ngwang, B., et al. (2012). A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood, 119(15), 3571\u20133577. https:\/\/doi.org\/10.1182\/blood-2011-06-364182","journal-title":"Blood"},{"issue":"3","key":"11195_CR63","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ijc.29410","volume":"137","author":"VT Hoang","year":"2015","unstructured":"Hoang, V. T., Buss, E. C., Wang, W., et al. (2015). The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. International Journal Of Cancer, 137(3), 525\u2013536. https:\/\/doi.org\/10.1002\/ijc.29410","journal-title":"International Journal Of Cancer"},{"key":"11195_CR64","doi-asserted-by":"publisher","unstructured":"Stelmach, P., & Trumpp, A. (2023). Leukemic stem cells and therapy resistance in acute myeloid leukemia.Haematologica ;108(2):353\u2013366. https:\/\/doi.org\/10.3324\/haematol.2022.280800","DOI":"10.3324\/haematol.2022.280800"},{"issue":"5","key":"11195_CR65","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/ijlh.14348","volume":"46","author":"T Reuvekamp","year":"2024","unstructured":"Reuvekamp, T., Bachas, C., & Cloos, J. (2024). Immunophenotypic features of early haematopoietic and leukaemia stem cells. International Journal of Laboratory Hematology, 46(5), 795\u2013808. https:\/\/doi.org\/10.1111\/ijlh.14348","journal-title":"International Journal of Laboratory Hematology"},{"issue":"7","key":"11195_CR66","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730\u2013737. https:\/\/doi.org\/10.1038\/nm0797-730","journal-title":"Nature Medicine"},{"key":"11195_CR67","doi-asserted-by":"publisher","first-page":"108626","DOI":"10.1016\/j.biotechadv.2025.108626","volume":"83","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y., Yu, W., Yuan, D., Ma, W., Tu, Y., & He, B. (2025). Epigenetic therapy for leukemias: a comprehensive review from biological markers to practice. Biotechnology Advances, 83, 108626. https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108626","journal-title":"Biotechnology Advances"},{"issue":"1","key":"11195_CR68","doi-asserted-by":"publisher","first-page":"101613","DOI":"10.1016\/j.beha.2025.101613","volume":"38","author":"P Smallbone","year":"2025","unstructured":"Smallbone, P., Kebriaei, P., Mendt, M., Shpall, E. J., Olson, A. L., & Fingrut, W. B. (2025). Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions. Best Practice & Research. Clinical Haematology, 38(1), 101613. https:\/\/doi.org\/10.1016\/j.beha.2025.101613","journal-title":"Best Practice & Research. Clinical Haematology"},{"issue":"4","key":"11195_CR69","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1007\/s12015-026-11078-9","volume":"22","author":"D Bhartiya","year":"2026","unstructured":"Bhartiya, D. (2026). Relationship between VSELs, MUSE Cells and MSCs in health and disease. Stem Cell Rev Rep, 22(4), 2050\u20132060. https:\/\/doi.org\/10.1007\/s12015-026-11078-9","journal-title":"Stem Cell Rev Rep"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11195-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:59:01Z","timestamp":1788764341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11195-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11195"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11195-5","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We have.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors work at TZAR Genomics, which has an interest in early detection of cancer with a focus on VSELs that are mobilized into the peripheral blood.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}